This is part two of IndyStar's oral history recounting the national blowback to the Religious Freedom Restoration Act in 2015.

This is part two of IndyStar's oral history recounting the national blowback to the Religious Freedom Restoration Act in 2015. Read part one here. Tension had been building against Indiana's ...

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

It’s bulking season for Mark Wahlberg. The Hollywood actor candidly shared his fitness journey with his 30.9 million followers on social media after he stripped down to nothing but his shorts.

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Showcasing a limited-edition, hand-painted print, the new collection features coordinating styles for kids and adults. By Erin Lassner E-Commerce Writer If you purchase an independently reviewed ...

A Mark Ronson performance didn’t go so well for him. The award-winning producer and artist shared on social media that he hurt himself during a recent DJ set. The “Uptown Funk” star posted a ...

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer.

Mark Ronson landed in the hospital after he pulled two bicep tendons during a recent DJ set. On Wednesday, the 49-year-old musician detailed how he got his injury, writing in an Instagram post ...

Weight loss drugs such as Mounjaro help the body manage blood sugar more effectively, make one feel less hungry, and slow digestion, so the person feels full longer. Mounjaro, chemically known as ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...